As of 2025-07-20, the EV/EBITDA ratio of Ascletis Pharma Inc (1672.HK) is -23.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 1672.HK's latest enterprise value is 8,555.36 mil HKD. 1672.HK's TTM EBITDA according to its financial statements is -361.85 mil HKD. Dividing these 2 quantities gives us the above 1672.HK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 23.6x - 29.3x | 26.3x |
| Forward P/E multiples | 9.4x - 14.9x | 10.5x |
| Fair Price | (8.73) - (5.14) | (6.58) |
| Upside | -188.7% - -152.1% | -166.8% |
| Date | EV/EBITDA |
| 2025-07-18 | -219.76 |
| 2025-07-17 | -185.92 |
| 2025-07-16 | -172.35 |
| 2025-07-15 | -174.45 |
| 2025-07-14 | -166.81 |
| 2025-07-11 | -167.00 |
| 2025-07-10 | -170.06 |
| 2025-07-09 | -167.57 |
| 2025-07-08 | -164.32 |
| 2025-07-07 | -174.64 |
| 2025-07-04 | -177.70 |
| 2025-07-03 | -180.00 |
| 2025-07-02 | -164.70 |
| 2025-06-30 | -170.82 |
| 2025-06-27 | -162.22 |
| 2025-06-26 | -171.59 |
| 2025-06-25 | -175.22 |
| 2025-06-24 | -183.82 |
| 2025-06-23 | -183.06 |
| 2025-06-20 | -181.53 |
| 2025-06-19 | -168.15 |
| 2025-06-18 | -182.86 |
| 2025-06-17 | -173.12 |
| 2025-06-16 | -200.64 |
| 2025-06-13 | -178.09 |
| 2025-06-12 | -180.95 |
| 2025-06-11 | -165.85 |
| 2025-06-10 | -158.78 |
| 2025-06-09 | -154.38 |
| 2025-06-06 | -143.87 |
| 2025-06-05 | -145.21 |
| 2025-06-04 | -151.90 |
| 2025-06-03 | -155.91 |
| 2025-06-02 | -150.18 |
| 2025-05-30 | -144.25 |
| 2025-05-29 | -133.35 |
| 2025-05-28 | -136.22 |
| 2025-05-27 | -133.93 |
| 2025-05-26 | -120.74 |
| 2025-05-23 | -123.41 |
| 2025-05-22 | -124.18 |
| 2025-05-21 | -131.44 |
| 2025-05-20 | -118.06 |
| 2025-05-19 | -105.45 |
| 2025-05-16 | -102.39 |
| 2025-05-15 | -112.71 |
| 2025-05-14 | -109.08 |
| 2025-05-13 | -115.96 |
| 2025-05-12 | -112.90 |
| 2025-05-09 | -123.99 |